News & Updates
Filter by Specialty:
Long-term relugolix combo helps with heavy periods, anaemia in women with uterine fibroids
Treatment with relugolix combination for up to 52 weeks yields sustained reductions in heavy menstrual bleeding as well as subsequent increases in iron stores in women with uterine leiomyomas, as shown in a study.
Long-term relugolix combo helps with heavy periods, anaemia in women with uterine fibroids
16 Nov 2022
Pretreatment sarcopenic assessments help predict gynaecologic cancer outcomes
Pretreatment sarcopenia appears to worsen survival in patients with gynaecologic cancers, such as ovarian (OC), endometrial (EC), and cervical (CC), reports a study. Including this assessment into cancer management may help improve prognosis.
Pretreatment sarcopenic assessments help predict gynaecologic cancer outcomes
15 Nov 2022
Dolutegravir: A better choice for HIV viral suppression in pregnancy?
Among pregnant individuals on antiretroviral therapy (ART) for HIV-1 infection, those on dolutegravir had the greatest viral suppression rates at delivery, a recent US-based observational study showed. However, birth outcomes generally did not differ between dolutegravir recipients and those on various other ART regimens.
